Toggle light / dark theme

Dr. Hassan A. Tetteh, MD, is the Health Mission Chief, at the Department of Defense (DoD) Joint Artificial Intelligence Center, serving to advance the objectives of the DoD AI Strategy, and improve war fighter healthcare and readiness with artificial intelligence implementations.

Dr. Tetteh is also an Associate Professor of Surgery at the Uniformed Services University of the Health Sciences, adjunct faculty at Howard University College of Medicine, a Thoracic Staff Surgeon for MedStar Health and Walter Reed National Military Medical Center, and leads a Specialized Thoracic Adapted Recovery (STAR) Team, in Washington, DC, where his research in thoracic transplantation aims to expand heart and lung recovery and save lives.

In the past, Dr. Tetteh has served as Chief Medical Informatics Officer, United States Navy, and Division Lead for Futures and Innovation at Navy Medicine’s Headquarters, a Command Surgeon for the National Defense University, and as a Robert Wood Johnson Health Policy Fellow, assigned to the U.S. Congress, Congressional Budget Office, (CBO).

Dr. Tetteh served as Ship’s Surgeon and Director of Surgical Services for the USS Carl Vinson battle group in support of Operation Iraqi Freedom, deployed as a trauma surgeon to Afghanistan’s Helmand and Nimroz provinces in support of Operation Enduring Freedom, and has supported special joint forces missions to South America, the Middle East, the South Pacific, Australia, and Africa. He earned both the Surface Warfare Medical Department Officer and Fleet Marine Force Qualified Officer designations, and his military honors include two Meritorious Service Medals and the Joint Service Commendation Medal.

What do you think Eric Klien.


A universal basic income worth about one-fifth of workers’ median wages did not reduce the amount of effort employees put into their work, according to an experiment conducted by Spanish economists, a sign that the policy initiative could help mitigate inequalities and the impact of automation.

Providing workers with a universal basic income did not reduce the amount of effort they put into their work, according to an experiment conducted by Spanish economists, a sign that the policy initiative could help mitigate inequalities and debunking a common criticism of the proposal.

Examining a universal basic income worth about one-fifth of workers’ median wages, the researchers also found that the threat of being replaced by robots did not impact workers’ productivity, nor did a tax on firms when they replace a worker with a robot or automated process, though the latter successfully created a disincentive for managers.

NHS clinicians in England will be among the first to offer a cutting-edge personalised cancer treatment to some people with lymphoma, after the CAR T cell therapy was approved for NHS use.

Tecartus – a immune-boosting treatment that engineers a patient’s own immune cells to kill their cancer – has been recommended by the National Institute for Health and Care Excellence (NICE) for people with a rare type of non-Hodgkin lymphoma.

NICE estimates that around 100 people a year with mantle cell lymphoma could be treated with this therapy. Kruti Shrotri, head of policy development at Cancer Research UK, said the news will be welcomed by people with mantle cell lymphoma.

But the MIT report also acknowledges that while fears of an imminent jobs apocalypse have been over-hyped, the way technology has been deployed over recent decades has polarized the economy, with growth in both white-collar work and low-paid service work at the expense of middle-tier occupations like receptionists, clerks, and assembly-line workers.

This is not an inevitable consequence of technological change, though, say the authors. The problem is that the spoils from technology-driven productivity gains have not been shared equally. The report notes that while US productivity has risen 66 percent since 1978, compensation for production workers and those in non-supervisory roles has risen only 10 percent.

“People understand that automation can make the country richer and make them poorer, and that they’re not sharing in those gains,” economist David Autor, a co-chair of the task force, said in a press release. “We need to restore the synergy between rising productivity and improvements in labor market opportunity.”

Is the author of the book Free To Choose Medicine: Better Drugs Sooner at Lower Cost; a book that offers a compelling argument for the freedom of every patient, guided by the advice of his or her doctor, to make informed decisions about the use of not-yet-FDA-approved therapeutic drugs, that are in late stages of clinical testing.

Mr. Madden is recently retired as a Managing Director of Credit Suisse/Holt after a career in money management and investment research that included the founding of Callard Madden & Associates. During his career, he developed the cash-flow return on investment (CFROI) valuation framework that is widely used today by money management firms worldwide.

Mr. Madden is currently an independent researcher and a Senior Fellow at the National Center for Policy Analysis (NCPA). His research has focused on the themes of knowledge building and wealth creation being able to exist simultaneously in businesses, and these themes are represented in his various books including — Value Creation Principles: The Pragmatic Theory of the Firm Begins with Purpose and Ends with Sustainable Capitalism, Wealth Creation: A Systems Mindset for Building and Investing in Businesses for the Long Term, and Reconstructing Your Worldview: The Four Core Beliefs You Need to Solve Complex Business Problems.

Mr. Madden is a proponent of the application of systems thinking to public policy, and his work in public policy has resulted in the Free To Choose Medicine (http://freetochoosemedicine.com/) plan, which was originally developed in journal articles published in Regulation, Cancer Biotherapy & Radiopharmaceuticals, and Medical Hypotheses.

COSPAR’s Planetary Protection Policy ensures scientific investigations related to the origin and distribution of life are not compromised.


Protecting the Earth from alien life sounds like the latest plot for a blockbuster thriller set in outer space. Whether it’s an invasion or a mysterious alien illness, the extraterrestrial threat to our planet has been well-explored in science fiction. But protecting the Earth from extraterrestrial contamination is not just a concept for our entertainment; as we explore further across our solar system and begin to land on our neighbouring planetary bodies, ensuring that we don’t bring potentially dangerous material home to Earth or indeed carry anything from Earth that may contaminate another planet is a responsibility we must take seriously.

So, who is responsible for ensuring that our space exploration is completed safely? Many nations around the world have their own space agencies, such as NASA and the European Space Agency, who run many different types of missions to explore space. States are responsible for their space activities under the Outer Space Treaty of 1967, including governmental and non-governmental actors. The Outer Space Treaty, among several provisions, regulates in its Article IX against harmful contamination. One of the core activities of the Committee on Space Research (COSPAR) is to develop, maintain, and promote a Policy on Planetary Protection, as the only international reference standard for spacefaring nations and in guiding compliance with Article IX of the Outer Space Treaty.

As we explore further across our solar system, ensuring we don’t bring potentially dangerous material home or indeed carry anything from Earth that may contaminate another planet and compromise scientific investigations is a responsibility we must take seriously.

There they go again. Just a few months ago the US Department of Energy tapped a startup called Group14 Technologies for a multi-million dollar R&D grant to usher in a new generation of high performance EV batteries, and now here comes Group14 with another $17 million in series B funding spearheaded by the South Korean battery expert SK Materials. If you guessed that means scaling up production for the mass market, you’re right on the money. The bigger question is why the Energy Department is determined to support the US electric vehicle industry, considering that White House policy has been aimed at supporting the US oil industry. Any guesses?

It seems competition is increasing.


BEIJING – In a future driven by electric vehicles, China is poised to dominate if the U.S. does not transform its automobile industry in coming years.

While California-based Tesla captured popular attention for electric cars, national policy in Beijing encouraged the launch of several rivals in China, the world’s largest auto market. Already, sales of electric cars and other new energy vehicles hit a record in September in China. Even Tesla launched a factory there last year, and is planning to sell made-in-China cars to Europe.

Powering it all are electric batteries – of which two Chinese companies, Contemporary Amperex Technology (CATL) and BYD, account for about a third of the global market, according to UBS. All six of the major battery manufacturers identified by UBS are Asian.

It seems some countries are now switching to drone swarms.


From Syria to Libya to Nagorno-Karabakh, this new method of military offense has been brutally effective. We are witnessing a revolution in the history of warfare, one that is causing panic, particularly in Europe.

In an analysis written for the European Council on Foreign Relations, Gustav Gressel, a senior policy fellow, argues that the extensive (and successful) use of military drones by Azerbaijan in its recent conflict with Armenia over Nagorno-Karabakh holds “distinct lessons for how well Europe can defend itself.”